Morphosys

MONJUVI

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Morphosys

Monjuvi HCPCS:

J9349

HCPCS Code Descriptor:

Injection, tafasitamab-cxix, 2 mg

Category:

J Code

Monjuvi NDCs:

73535-0208-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Monjuvi CPT Codes:

-96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug

-96415 - Chemotherapy administration, intravenous infusion technique; each additional hour, 1-8 hours (List separately in addition to code for primary procedure)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Monjuvi:

MONJUVI is an Oncology drug manufactured by Morphosys and administered via the Intravenous route of administration. The J Code: J9349 is aligned to the drug MONJUVI.

ACCESS PRICING AND MORE BY REGISTERING

J9349 Added Date:

April 1, 2021

J9349 Effective Date:

April 1, 2021

J9349 Termination Date:

HCPCS Active

Monjuvi billing and coding information can be found through Morphosys at the link below:
Monjuvi patient assistance information can be found through My MISSION Support at the URL: https://www.mymissionsupport.com/
MONJUVI prescribing information can be found at the link below:
Information regarding MONJUVI’s side effects can be found at MedlinePlus